
BenevolentAI Ltd inks US$594m partnership with Merck KGaA
Under the licence agreement, BenevolentAI will identify and develop new compounds against three targets provided by Merck through hit identification...

BioSpain breaking records
On its 20th anniversary in Catalonia’s vibrant capital Barcelona, BioSpain 2023 is set to break records in terms of attracting visitors,...

AstronauTx closes £48m Series A financing
The finanicing round of AstronauTx Ltd was led by the Novartis Venture Fund, with participation of MPM Capital, Brandon Capital, EQT Life Sciences,...

Alfasigma SpA set to take over Galapagos programme
Under the planned agreement, Alfasigma SpA will pay €50m upfront, milestones totaling €120m and mid-single to mid-double digit royalties on European...

Pierre Fabre Laboratories acquires Vertical Bio
The acquisition of Vertical Bio AG for an undisclosed amount of money allows Pierre Fabre Laboratories to...

Pierre Fabre SA licences immunotherapy from Atara Biotherapeutics
Paris-based Pierre Fabre Laboratories SA already held a licence for the EU-approved tabelecleucel, an allogeneic T cell based second-line treatment...

Orakl Oncology SA raises €3m to advance tumour modelling
French precision oncology start-up Orakl Oncology has raised €3m in a seed financing round led by Speedinvest with additional investment from...